What’s the current market cap for Insulet stock?

Insulet (PODD) has a market cap of $9.6bn as of June 23, 2026.

What is the P/E ratio for Insulet stock?

The price to earnings (P/E) ratio for Insulet (PODD) stock is 32.4 as of June 23, 2026.

Does Insulet stock pay dividends?

No, Insulet (PODD) stock does not pay dividends to its shareholders as of June 23, 2026.

When is the next Insulet dividend payment date?

Insulet (PODD) stock does not pay dividends to its shareholders.

What is the beta indicator for Insulet?

Insulet (PODD) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Insulet stock | $PODD Share Price

13:30

15:10

16:45

18:25

20:00

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Ticker

$PODD

Sector

Health

Primary listing

NASDAQ

Employees

5,400

Headquarters

Acton, United States

Website

www.insulet.com

Insulet Metrics

BasicAdvanced

$9.6bn

32.40

$4.29

1.20

What the Analysts think about Insulet

Analyst ratings (Buy, Hold, Sell) for Insulet stock.

Bulls say / Bears say

Insulet’s Q1 2026 revenue climbed 34 percent year-over-year to $761.7 million, beating analyst estimates and exceeding the upper end of its guidance range. (Reuters)

International Omnipod revenue surged 59.4 percent to $242.9 million, driven by faster adoption in new markets and diversifying Insulet's revenue stream. (Reuters)

The Omnipod 5 automated insulin delivery system received FDA approval for both type 1 and type 2 diabetes, expanding Insulet’s addressable market and supporting future growth. (Reuters)

Insulet initiated a voluntary correction for about 7 million Omnipod pods because of a manufacturing defect, anticipating up to $50 million in related costs. This creates both reputational and financial risk. (Fierce Biotech)

The recall covers pods that make up roughly 8.5 percent of Insulet’s global pod production in 2025, which could restrict supply for new patient starts and potentially slow revenue momentum. (Reuters)

Insulet trades at a premium valuation, with a P/E ratio of 36.11 and a P/B ratio of 8.22, both substantially higher than its medical device peers. This leaves little room for multiple expansion and increases downside risk if growth slows. (Investing.com)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Insulet Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Insulet Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Insulet’s Q1 2026 revenue climbed 34 percent year-over-year to $761.7 million, beating analyst estimates and exceeding the upper end of its guidance range. (Reuters)

International Omnipod revenue surged 59.4 percent to $242.9 million, driven by faster adoption in new markets and diversifying Insulet's revenue stream. (Reuters)

The Omnipod 5 automated insulin delivery system received FDA approval for both type 1 and type 2 diabetes, expanding Insulet’s addressable market and supporting future growth. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About Insulet

Ticker

Employees

Insulet Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Insulet

Analyst Ratings

Bulls say / Bears say

Insulet Financial Performance

Income Statement

Insulet Earnings Performance

Earnings per share (EPS)

Insulet News

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost

Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand

Buy $PODD

Lightyear

Legal

Work with us

Bulls say / Bears say

Insulet/$PODD

About Insulet

Ticker

Employees

Insulet Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Insulet

Analyst Ratings

Bulls say / Bears say

Insulet Financial Performance

Income Statement

Insulet Earnings Performance

Earnings per share (EPS)

Insulet News

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost

Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand

What’s the current market cap for Insulet stock?

What is the P/E ratio for Insulet stock?

Does Insulet stock pay dividends?

When is the next Insulet dividend payment date?

What is the beta indicator for Insulet?

Bulls say / Bears say